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Background: Individual metacognitive therapy (MCT) for generalized anxiety disorder (GAD) is well established, but only one study
has investigated the effectiveness of Group MCT (g-MCT) for GAD. The aim of the current study was therefore to evaluate the
feasibility and effectiveness of g-MCT for GAD within a community mental health setting whilst addressing limitations evident in
the previous study.
Method: The study used an open trial design, and 23 consecutively referred adults with GAD completed 10 sessions (90 minutes) of
g-MCT, delivered by two therapists trained in MCT. Diagnoses were assessed by trained raters using the Anxiety Disorder
Interview Schedule-IV. All patients but one had previous psychosocial treatment, and 17 (73.9%) had at least one comorbid axis-I
disorder. Self-reported symptoms were assessed using the Penn State Worry Questionnaire, the Generalized Anxiety Disorder-7,
and the Patient Health Questionnaire-9 at pre- and post-treatment as well as 3-month follow-up. Feasibility was assessed using
rates of patients who declined group treatment in favour of individual treatment, patients not able to attend due to pre-scheduled
dates for sessions, and drop-out rate.
Results: Of 32 eligible participants, six patients (19%) declined g-MCT in favour of individual MCT, and three (9%) were unable to
attend due to scheduling conflicts. No patients dropped out during treatment, but two patients did not complete the self-report
questionnaires at 3-month follow-up. g-MCT was associated with significant reductions in worry, anxiety, depression,
metacognitive beliefs, and maladaptive coping. According to the standardised Jacobson criteria for recovery, 65.2% were
recovered at post-treatment, whereas 30.4% were improved and 4.3% showed no change. At 3-month follow-up, the recovery rate
increased to 78.3%. Moreover, recovery rates were comparable for patients with- and without comorbidity. Number of therapist
hours per patient was 6.5 and the treatment has now been implemented as a standard treatment option at the clinic.
Conclusion: g-MCT for GAD is an acceptable treatment which may offer a cost-effective alternative approach to individual MCT.
Recovery rates and effect sizes suggested that g-MCT could be just as efficient as individual MCT and cognitive behavioural therapy.
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Abstract 38 
 39 
Background: Individual metacognitive therapy (MCT) for generalized anxiety disorder 40 
(GAD) is well established, but only one study has investigated the effectiveness of Group 41 
MCT (g-MCT) for GAD. The aim of the current study was therefore to evaluate the feasibility 42 
and effectiveness of g-MCT for GAD within a community mental health setting whilst 43 
addressing limitations evident in the previous study.  44 
 45 
Method: The study used an open trial design, and 23 consecutively referred adults with GAD 46 
completed 10 sessions (90 minutes) of g-MCT, delivered by two therapists trained in MCT. 47 
Diagnoses were assessed by trained raters using the Anxiety Disorder Interview Schedule-IV. 48 
All patients but one had previous psychosocial treatment, and 17 (73.9%) had at least one 49 
comorbid axis-I disorder. Self-reported symptoms were assessed using the Penn State Worry 50 
Questionnaire, the Generalized Anxiety Disorder-7, and the Patient Health Questionnaire-9 at 51 
pre- and post-treatment as well as 3-month follow-up. Feasibility was assessed using rates of 52 
patients who declined group treatment in favour of individual treatment, patients not able to 53 
attend due to pre-scheduled dates for sessions, and drop-out rate.  54 
 55 
Results: Of 32 eligible participants, six patients (19%) declined g-MCT in favour of 56 
individual MCT, and three (9%) were unable to attend due to scheduling conflicts. No 57 
patients dropped out during treatment, but two patients did not complete the self-report 58 
questionnaires at 3-month follow-up. g-MCT was associated with significant reductions in 59 
worry, anxiety, depression, metacognitive beliefs, and maladaptive coping. According to the 60 
standardised Jacobson criteria for recovery, 65.3% were recovered at post-treatment, whereas 61 
30.4% were improved and 4.3% showed no change. At 3-month follow-up, the recovery rate 62 
increased to 78.3%. Moreover, recovery rates were comparable for patients with- and without 63 
comorbidity. Number of therapist hours per patient was 6.5 and the treatment has now been 64 
implemented as a standard treatment option at the clinic. 65 
  66 
Conclusion: g-MCT for GAD is an acceptable treatment which may offer a cost-effective 67 
alternative approach to individual MCT. Recovery rates and effect sizes suggested that g-68 
MCT could be just as efficient as individual MCT and cognitive behavioural therapy. 69 
 70 
 71 
 72 
 73 
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Introduction 81 
Generalized anxiety disorder (GAD) is a common disorder associated with a chronic course 82 
and significantly reduced quality of life (APA, 2013; Spitzer et al., 2006). It is characterized 83 
by excessive and uncontrollable worry related to multiple events or activities, with a duration 84 
of six months or more (APA, 2013). Associated symptoms include restlessness, fatigue, 85 
difficulties concentrating, irritability, muscle tension, and sleep difficulties (APA, 2013).  86 
 87 
Cognitive behavioural therapy (CBT) is currently an evidence-based treatment for GAD 88 
(Hoyer et al., 2011). Meta-analyses show that CBT leads to a reduction in anxiety symptoms 89 
more so than treatment as usual or a waiting list (Covin et al., 2008; Hunot et al., 2007; Mitte, 90 
2005). However, based on the criteria for clinically significant change (Jacobson & Truax, 91 
1991), only 50-60% of patients with GAD recover at 6-month follow-up after CBT (Fisher & 92 
Durham, 1999). Thus, since a considerable proportion of GAD patients do not recover 93 
following CBT, more effective interventions are required.  94 
 95 
Metacognitive Therapy (MCT) for GAD is an alternative treatment to CBT. MCT focuses on 96 
changing thought processes rather than thought content (e.g., Wells, 1995). MCT is derived 97 
from the self-regulatory executive function (S-REF) model (Wells & Matthews, 1994; 1996). 98 
Maintenance of psychological problems is linked to the activation of the cognitive-attentional 99 
syndrome (CAS) consisting of repetitive thinking (worry and rumination), threat monitoring, 100 
and maladaptive coping behaviours. The CAS is a product of an individual’s metacognitive 101 
beliefs and knowledge. Central to the metacognitive model of GAD (Wells, 1995; 1997; 102 
2009) is that individuals’ thoughts and beliefs about worry (i.e. metacognitive beliefs) 103 
contribute to the development and maintenance of the disorder. Worry is often triggered by 104 
negative intrusive thoughts in the form of "what if" questions, e.g. "What if I'm involved in an 105 
accident?”. Thereafter, the use of worry is related to the activation of positive metacognitive 106 
beliefs about the advantages or benefits of worrying (Wells, 2009). Examples of such positive 107 
beliefs are "Worrying makes me prepared, and focusing on threat keep me safe".  108 
 109 
Symptoms of GAD escalate when negative metacognitive beliefs about worry are activated. 110 
Two types of negative beliefs are important: negative beliefs about the uncontrollability of 111 
worry (e.g. "I have lost control over my thoughts") and negative beliefs about the possible 112 
dangers of worry ("If I do not stop worrying, I will lose my mind"). The activation of negative 113 
metacognitive beliefs leads to worry about worry (also called “meta-worry” or “Type 2-114 
worry”), which intensifies worry, anxiety, and other maladaptive coping strategies. The model 115 
proposes that individuals with GAD tend to use worry as a coping strategy to safeguard 116 
against perceived threats and dangers. Examples of other frequently used coping responses 117 
among GAD patients are thought suppression, threat monitoring, distraction, avoidance, and 118 
reassurance seeking. These coping strategies backfire and consolidate the belief that worry is 119 
uncontrollable.  120 
 121 
The metacognitive model of GAD (Wells, 1995; 1997; 2009) proposes that both positive and 122 
negative metacognitive beliefs need to be modified to enable people to disengage from 123 
worrying in response to trigger thoughts. Furthermore, the model specifies that 124 
counterproductive coping strategies need to be modified if people are to successfully reduce 125 
worry.  126 
 127 
So far, four studies have evaluated MCT for GAD delivered individually for outpatients. 128 
Wells and King (2006) conducted an open trial (N = 10), where a range of 3-12 weekly MCT 129 
sessions were delivered. There were significant improvements in symptoms of worry, anxiety, 130 
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and depression at post-treatment (within-group d’s between 1.12 [health worry] and 2.78 131 
[trait-anxiety]) and follow-up (within-group d’s between 1.10 and 2.58), and 87.5% of the 132 
patients met criteria for recovery on trait-anxiety (STAI-T) at post-treatment, and 75% were 133 
recovered at 6- and 12-month follow-up.  134 
 135 
The second study was conducted by Wells et al. (2010) and was a randomized controlled trial 136 
(N = 20, 10 in each condition) where MCT was compared with applied relaxation (AR) in 137 
patients with GAD. Treatment sessions lasted 45-60 minutes and were held once per week for 138 
8-12 weeks. MCT was significantly more effective in reducing GAD symptoms than AR. 139 
Following criteria (Fisher & Durham, 1999) for clinically significant change (PSWQ; cut-off 140 
≤ 47, reliable change index: 7), the recovery rate was 80% in the MCT group at post-141 
treatment, compared with 10% in the AR group. At 6-month follow-up, the recovery rate was 142 
70% in the MCT group and 10% in the AR group, while the figure was 80% and 10%, 143 
respectively, at 12-month follow-up. High recovery rates combined with a large within-group 144 
effect size (d = 3.41) indicated that MCT was an effective treatment for GAD.  145 
 146 
Van der Heiden et al. (2012) investigated the effectiveness of MCT and intolerance of 147 
uncertainty therapy (IUT). Each treatment consisted of a maximum of 14 weekly sessions of 148 
45 minutes. Both MCT and IUT were associated with significant reductions in symptoms of 149 
GAD at post-treatment and 6-month follow-up, but MCT was found to be significantly 150 
superior to IUT. The within-group effect sizes for worry (PSWQ) in the MCT group were 151 
high at both post-treatment (d = 1.67) and follow-up (d = 1.66), and the between-group effect 152 
sizes were 0.96 at post-treatment and 0.78 at follow-up. In the MCT intention-to-treat group, 153 
60% met criteria for recovery on PSWQ (cut-off ≤ 53, reliable change index: 7) at end of 154 
treatment and 62% at follow-up. The corresponding recovery rates for the IUT group were 155 
37% and 47%, respectively. 156 
 157 
Nordahl et al. (2018) compared the efficacy of MCT and CBT for GAD. Both CBT and MCT 158 
produced significant reductions in worry (PSWQ) in comparison to the wait list group. 159 
However, MCT was found to be more effective than CBT. In the MCT condition 65% were 160 
classified as recovered post-treatment in comparison to 38% in the CBT condition, and the 161 
difference was maintained at 2-year follow-up.  162 
 163 
In summary, previous research indicates that individual outpatient MCT for GAD is well 164 
established. According to, the National Institute for Health and Clinical Excellence (NICE, 165 
2011) guidelines, MCT is a recommended treatment for GAD. However, group MCT (g-166 
MCT) for GAD has only been examined in one open trial (Van der Heiden et al., 2013). This 167 
study used large groups (10-14 patients) which may limit participation of some group 168 
members and not allow therapy to be implemented with sufficient specificity to address 169 
individual needs. In addition, two out of the four therapists had not received training in MCT 170 
thereby potentially limiting treatment adherence and competency. The sample consisted of 33 171 
outpatients, treatment sessions lasted 90 minutes and were held weekly for 12-14 weeks. 172 
There were significant reductions in worry, anxiety, and negative metacognitive beliefs. In the 173 
intention-to-treat sample, the between group effect sizes at post-treatment and six-month 174 
follow-up were 1.24 and 1.29 respectively. In terms of recovery, 55% of participants met 175 
criteria for clinically significant criteria at post-treatment recovery rate at post-treatment (cut-176 
off: ≤ 53, reliable change index: 7).  177 
 178 
 179 
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Treatment in a group can be an attractive alternative to individual treatment for several 180 
reasons. A similar effect as individual treatment will result in group treatment being more 181 
cost-effective by cutting down on long waiting lists leading to more effective use of the 182 
therapists’ time. One assumption is that MCT will be well-suited to a group format because it 183 
is based on a transdiagnostic model. A recent study supported the use of g-MCT for a 184 
transdiagnostic sample (Capobianco, Reeves, Morrison, & Wells, 2018). The study found that 185 
g-MCT was more effective than Mindfulness Based Stress Reduction in treating symptoms of 186 
anxiety and depression. Furthermore, patients with GAD may worry about different events, 187 
activities, life events and will frequently have different comorbid disorders, but MCT focuses 188 
on changing the attitudes and beliefs one has around thought processes (i.e. worrying and 189 
rumination) and is less concerned with the actual idiosyncratic thought content of each 190 
patient. Patients can help each other identify shared maladaptive metacognitive beliefs and 191 
coping strategies whilst their worry content differ. 192 
 193 
Despite the appealing aspect of group treatment, a comparison of effect sizes, recovery-, and 194 
attrition rates with previous studies of individual MCT indicates that g-MCT may be less 195 
effective. Furthermore, the dropout rate was higher in g-MCT (27%) than in individual 196 
treatment studies (van der Heiden et al., 2012: 18%; Wells et al., 2010 and Wells & King, 197 
2006: 0%). In addition to the limitations of the Van der Heiden et al. (2013) study, the authors 198 
also suggested several possible reasons for the differences from individual MCT. First, the 199 
large group size (10-14 patients per group) may have reduced the acceptability of the 200 
treatment modality and contributed to the high drop-out rate. Second, there may have been 201 
less time to identify and challenge each patient's idiosyncratic metacognitive beliefs, given the 202 
group size. Third, therapist factors may have comprised the effectiveness of the intervention 203 
as only two out of four therapists were trained in MCT, and there was no supervision in 204 
delivering g-MCT. 205 
 206 
In summary, even though van der Heiden et al.’s (2013) results indicated that g-MCT was 207 
effective in reducing GAD symptoms, many questions remain regarding the feasibility of g-208 
MCT, such as recruitment, group size, and retention. Consequently, the primary aim of the 209 
current study was to benchmark and evaluate the feasibility of g-MCT for adult patients with 210 
GAD. Moreover, to explore whether smaller groups would be more feasible and effective, as 211 
only 4-6 patients were included in each group. The study was conducted at a Norwegian 212 
psychiatric outpatient clinic without a control group. The secondary aim of the study was to 213 
evaluate the effectiveness of g-MCT, with the hypothesis being that g-MCT will be associated 214 
with significant reductions in symptoms of GAD and depression, as well as reductions in 215 
positive- and negative metacognitions, maladaptive coping strategies, and avoidance.  216 
 217 
 218 
Methods 219 
 220 
Participants 221 
The sample consisted of 23 participants, of which 22 were women (95.7%). The average age 222 
was 29.70 years (SD = 9.21). Further demographic characteristics are shown in Table 1. The 223 
four patients using antidepressants reported to use either Zoloft or Cipralex. Three of these 224 
four had been on a stable dose for years, while the fourth started medication four months 225 
before treatment. No changes were made to medication during treatment. In addition, two 226 
patients used medicine for sleep related problems.  227 
 228 
Table 1 here 229 
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 230 
Diagnosis was established using the Anxiety Disorder Interview Schedule (ADIS-IV, Brown 231 
et al., 1994). To be included in the present study, GAD had to be the primary diagnosis. None 232 
of the participants had known serious somatic illnesses, psychosis, post-traumatic stress 233 
disorder, known cluster A- or B personality disorders, were suicidal, or suffered from drug 234 
addiction. Seventeen (73.9%) participants had comorbid disorders. Fourteen had one 235 
comorbid disorder (OCD = 4, depression = 2, panic disorder = 3, social anxiety disorder = 1, 236 
specific phobia = 1, health anxiety = 1, ADHD = 2). Three patients had two comorbid 237 
diagnoses (one with panic disorder and depression, one with OCD and depression, and one 238 
with OCD and social phobia). 239 
 240 
Procedure 241 
The clinic has a population catchment of approximately 130,000 people. Patients were 242 
referred to the clinical service from their GP, student health services, and mental health 243 
clinics. The first group started in September 2016 and the last group started in October 2017. 244 
Patients included in the study were consecutive referrals.  245 
 246 
Pre-treatment assessment consisted of the ADIS-IV (Brown et al., 1994) and completion of 247 
self-report questionnaires. The ADIS-IV was conducted by independent investigators (clinical 248 
psychologists not involved with the treatment) trained in diagnostic interviewing. Patients 249 
received no treatment whilst waiting for treatment to start. The wait time period was 3-4 250 
months.  251 
 252 
Five groups were held, each with 4-6 patients. The groups were held at Nidaros DPS, St. 253 
Olavs Hospital. Patients were offered 10 weekly group sessions, each with a duration of 90 254 
minutes. All self-report questionnaires were completed at pre-treatment, post-treatment, and 255 
at 3-month follow-up. The first groups completed questionnaires on pen and paper at the 256 
clinic, while the more recent groups completed questionnaires online. In addition, the 257 
Generalized Anxiety Disorder Scale-Revised (GADS-R; Wells, 2009) was distributed before 258 
the beginning of each treatment session. The study was approved by the Regional Committees 259 
for Medical and Health Research Ethics (REK; 2013/2155, Helse Midt, 260 
https://helseforskning.etikkom.no/). 261 
 262 
Therapists 263 
All groups were led by two therapists; a psychiatric nurse and a clinical psychologist. Both 264 
had completed training in MCT and were registered level 1 and level 2 therapists respectfully. 265 
Video supervision was conducted with a master clinician in MCT. Furthermore, several 266 
groups had been conducted for training purposes before the open trial was initiated.  267 
 268 
Treatment 269 
The g-MCT had a specific structure and followed the treatment manual for GAD (Wells, 270 
2009). Sessions one and two focused on creating a group case formulation. Participants were 271 
helped to create their own personal case formulation. Participants were socialized to the 272 
metacognitive model and introduced to the concept of detached mindfulness (detached 273 
mindfulness; Wells, 2009). Sessions three and four focused on challenging metacognitive 274 
beliefs regarding uncontrollability of worry and the belief that they would lose control if they 275 
worried too much. In order to clarify conflicting and dysfunctional metacognitions, the group 276 
was divided into two smaller groups and they constructed arguments for worry being 277 
controllable or not, and if they could lose control or not. The participants then discussed and 278 
challenged each other's beliefs, with help from the therapists.  279 
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  280 
In sessions five and six the primary aim of MCT was to reduce negative beliefs about the 281 
dangers of worry. Both verbal and behavioural strategies were used to challenge 282 
metacognitions. Examples of verbal strategies were questioning the evidence of 283 
metacognitive beliefs and searching for counterclaims (as with beliefs about uncontrollability 284 
in earlier sessions). Thereafter, in session 7 and 8, positive beliefs about worry were 285 
challenged and modified.   286 
 287 
The last phase of therapy (session 9 and 10) focused on relapse prevention. The group 288 
members made a summary of their case formulation (therapy blueprint) and a summary (“old 289 
and new plan”) of how they used to respond to negative thoughts in the past and contrasted 290 
this with their new adaptive responses to worrying thoughts. 291 
 292 
Measures 293 
The Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990) is a 16-item self-report 294 
questionnaire measuring the severity of worry, both in terms of frequency, intensity and 295 
uncontrollability. Each item is rated from 1 (“not at all typical of me”) to 5 (“very typical of 296 
me”). The total score ranges from 16 to 80, where a higher score indicates higher levels of 297 
pathological worry. It has excellent internal consistency (Cronbach α = .93) and good 298 
psychometric properties (Meyer et al., 1990). Cronbach’s alpha in the current study was .97.  299 
 300 
Generalized Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006) is a self-report questionnaire 301 
with seven items assessing symptoms of GAD. Patients answer how much during the last two 302 
weeks they have been bothered by each symptom. The answer options range from 0 ("not at 303 
all") to 3 ("almost every day"), resulting in a total score between 0 and 21. A clinical cut-off 304 
point of 10 has been suggested. GAD-7 has been shown to have excellent internal consistency 305 
(Cronbach α = .92) and good test-retest reliability (r = 0.83). It has also demonstrated good 306 
criterion, construct, factorial, and procedural validity (Spitzer et al., 2006). Cronbach’s alpha 307 
in the current study was .89.  308 
 309 
The Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001) is a self-report 310 
questionnaire designed to measure symptoms of depression using nine items corresponding to 311 
the nine criteria for depression. The patient answers how troublesome each problem has been 312 
during the past two weeks, where each question is scored on a scale of 0 ("not at all") to 3 313 
("almost every day"). The total score range from 0 to 27, of where a cut point of 10 identifies 314 
major depression with good sensitivity and specificity (Kroenke et al., 2001). The PHQ-9 has 315 
demonstrated excellent internal reliability (Cronbach α = .86) and test-retest reliability, as 316 
well as good construct and convergent validity (Kroenke et al., 2001). Cronbach’s alpha in the 317 
current study was .90.  318 
 319 
Generalized Anxiety Disorder Scale-Revised (GADS-R; Wells, 2009) is a self-report 320 
inventory based on the metacognitive model of GAD. The first items cover GAD symptoms, 321 
time spent worrying, as well as how often a range of coping and avoidance behaviour have 322 
been done the last week. These items are scored on a scale from 0 to 8. In addition, the 323 
GADS-R assesses negative and positive metacognitive beliefs related to worry (Wells, 2009), 324 
each measured on a scale from 0 (“I do not believe this at all”) to 100 (“I’m completely 325 
convinced this is true”). Cronbach’s alpha for the coping items was .94, .79 for avoidance 326 
items, and .94 for the metacognitive belief items (.94 for negative beliefs and .93 for positive). 327 
 328 
Data analysis 329 
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The feasibility of g-MCT was operationalized and visualized through the participant flow 330 
chart (Figure 1), of where recruitment and retention rates are important feasibility outcomes. 331 
The results are contrasted with the g-MCT study of van der Heiden et al. (2013).  332 
 333 
A repeated measures ANOVA was used to investigate changes in worry and symptoms of 334 
anxiety and depression. The same test was used to measure changes in metacognitions, coping 335 
strategies, and avoidance. There was no significant skewness or kurtosis on pre-treatment 336 
measures. Mauchly's test of sphericity was not significant for all analyses using repeated 337 
measures ANOVA, except for PHQ-9, negative beliefs, and positive beliefs.  338 
 339 
Effect sizes (Cohen, 1992) were calculated with Morris & Deshon's Equation No. 8, which 340 
controls the correlation between pre- and post-treatment values of the dependent variable. 341 
Following Jacobson and Truax (1991) and Fisher (2006), recovery (clinically significant 342 
change on the PSWQ) was calculated with the following criteria: cut-off = 47, reliable change 343 
index = 7. The study uses a cut-off point and a reliable change index that has been applied to 344 
a large group of GAD patients and use the standardised criteria as described in Fisher (2006). 345 
These criteria have been used in all other MCT studies for GAD except for the van der 346 
Heiden et al. (2013) study. Using the standardised criteria allows benchmarking of the results 347 
and allows a reasonable comparison between individual and group MCT. Along with effect 348 
sizes, recovery rates were used to compare the treatment effectiveness of the current study 349 
with previous studies of both individual and group based MCT for GAD.  350 
 351 
Two patients did not complete questionnaires at follow-up. These values were replaced using 352 
last observation carried forward (one classified as improved and one as a treatment non-353 
responder). There were no other missing values at pre-treatment, post-treatment, or follow-up. 354 
Missing values for session-to-session data were not replaced.   355 
 356 
Lastly, the potential influence of comorbid disorders on treatment outcome was investigated 357 
using independent t-tests. The PSWQ, GAD-7, and PHQ-9 scores of patients with and 358 
without comorbid disorders were compared at pre-treatment, post-treatment, and 3-month 359 
follow-up.  360 
 361 
 362 
Results 363 
 364 
Feasibility 365 
As shown in the participant flow chart (Figure 1), 45 patients were referred to and assessed 366 
for inclusion in the current study. Twenty-three patients were entered into the study and  22 367 
patients were excluded. The most common reason for exclusion was that GAD was not the 368 
primary diagnosis (n = 9). Furthermore, two patients were excluded due to serious somatic 369 
disorder, and another two patients were given inpatient treatment instead of outpatient 370 
treatment because of their symptom severity and low level of functioning. Six patients 371 
preferred individual treatment instead of group treatment, and three patients could not 372 
participate in g-MCT due to practical difficulties. Therefore approximately 75% of suitable 373 
patients were included in the study. More specifically, 28.1% i.e. 9 of the 32 offered g-MCT 374 
declined. 375 
  376 
Patients attended a mean of 8.9 (SD = 1.3). sessions. More specifically: one patient attended 377 
five sessions (due to scheduling conflicts), two received seven sessions, four received eight 378 
sessions, seven received nine sessions, and nine patients attended all ten sessions. Number of 379 
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sessions were not significantly correlated with symptoms at post-treatment (r = .32 p = .13) or 380 
follow-up (r = .35, p = .10). Patients were asked to give their feedback on treatment 381 
acceptability in the tenth and final treatment session. For each group, all patients reported that 382 
they would have preferred group treatment rather than individual treatment because they were 383 
able to meet other patients which enabled them to learn from each other, and that the group 384 
setting reduced stigma related problems. 385 
 386 
After completion of the open trial, the two therapists reported that delivering treatment in a 387 
group format was clinically appropriate and that the small group format need not prevent any 388 
patients from fully participating in the therapy. Furthermore, the clinicians plan to continue to 389 
use g-MCT in their routine clinical practice as it is cost-effective and reduces the length of 390 
time patients have to wait for treatment   391 
 392 
No patients dropped out during treatment, but two patients did not complete the self-report 393 
questionnaires at 3-month follow-up. 394 
 395 
Figure 1 here 396 
 397 
 398 
Treatment effect 399 
  400 
Table 2 shows the mean and standard deviations for pre- and post-treatment scores and 3-401 
month follow-up. A repeated measures ANOVA was conducted to investigate changes. 402 
Mauchley's test was not significant on any of the analyses (except for PHQ-9, and negative- 403 
and positive metacognitions), and Wilks' lambda was therefore used. The results show 404 
significant improvements and large effect sizes for all measures. Linear mixed model analysis 405 
was also attempted with these data. However, all slopes went in the same direction as the 406 
results were unambiguous. Furthermore, there were no significant fixed effects only a clear 407 
effect of time. Model fit did not significantly improve when including attendance rate and age 408 
into the model compared to a simple model. 409 
 410 
Table 2 here 411 
 412 
Changes in symptoms were significant from pre-treatment to post-treatment, and there were 413 
non-significant changes from post-treatment to follow-up for all three measures. In addition to 414 
tests of statistical significance, clinically significant change was investigated. Only one 415 
patient did not respond to treatment. A summary of recovery rates are displayed in Table 3.  416 
 417 
Table 3 here 418 
 419 
Patients with comorbid disorders did not have significantly more symptoms than patients with 420 
no comorbidity at any of the three times of assessment. For PSWQ there was no significant 421 
difference at pre-treatment, t(21) = 0.96, p = .35, at post-treatment, t(21) = 1.82, p = .08, or 422 
follow-up, t(21) = 1.27, p = .22. Five of the six (83.3%) patients without comorbid disorders 423 
were recovered at follow-up compared to 76.5% for patients with comorbid disorders. For 424 
GAD-7 there was also no difference at pre-treatment, t(21) = 0.36, p = .73, at post-treatment, 425 
t(21) = 0.55, p = .73, or follow-up, t(21) = .71, p = .49. Same observation was made for PHQ-426 
9 at pre-treatment, t(21) = 0.61, p = .55, at post-treatment, t(21) = 1.34, p = .19, and at follow-427 
up, t(21) = .32, p = .76.  428 
 429 
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Metacognitive changes from session to session 430 
GADS-R was completed by patients before every session to measure changes in symptoms, 431 
worry, metacognitions, coping strategies, and avoidance.  432 
 433 
Table 4 here 434 
 435 
 436 
Table 4 shows a general decrease in all MCT related factors from session 1 to session 10. In 437 
general, the graph shows that treatment was associated with reductions in symptoms, worry, 438 
negative- and positive metacognitions, maladaptive coping strategies, and avoidance. 439 
 440 
Comparison with other GAD trials 441 
For benchmarking purposes, uncontrolled effect sizes (all outcome measures using the 442 
PSWQ) were compared to the previously mentioned studies of MCT for GAD (Wells et al., 443 
2010; Nordahl et al., 2018; van der Heiden et al., 2012; van der Heiden et al., 2013). Figure 2 444 
shows effect sizes (using pooled standard deviations) from pre-treatment to post-treatment 445 
and from pre-treatment to follow-up for the various studies. The results suggested that 446 
patients in the current study had obtained large reductions in symptoms of worry that were 447 
comparable even with individual MCT for GAD. Patients in the current study had quite high 448 
scores on PSWQ at pre-treatment, whereas post-treatment and follow-up scores were 449 
comparable with results from individual MCT. T-tests comparing the results of the current 450 
study with that of Wells et al. (2010) showed that the current study had a significantly higher 451 
PSWQ pre-treatment score, t(31) = 2.86, p = .007, while there was no significant difference at 452 
post-treatment, t(31) = 0.14, p = .889 and follow-up, t(31) = 0.55, p = .587.  453 
 454 
The average number of therapist hours per patient in this study was 6.5 hours (10 session x 455 
1.5 hrs x 2 therapists * 5 groups / 23 patients = 6.5), which accounts for fewer hours per 456 
patient compared to van der Heiden et al. (2012) and Wells et al. (2010) which had 10-12 457 
sessions (45-60 minutes each) per patient. 458 
  459 
Figure 2 here 460 
 461 
  462 
Discussion 463 
The aims of the current study were to evaluate the feasibility and effectiveness of g-MCT for 464 
patients with GAD within the context of an ordinary psychiatric clinic. As only a small 465 
proportion of patients declined g-MCT in favour of individual MCT and no patients dropped 466 
out during treatment, g-MCT appeared to be an acceptable treatment modality. Furthermore, 467 
g-MCT was associated with significant reductions in worry and symptoms of anxiety and 468 
depression. There were also significant reductions in all MCT related factors such as positive 469 
metacognitive beliefs, negative metacognitive beliefs, and maladaptive coping strategies 470 
(including avoidance behaviour). Session to session ratings indicated that the reduction in 471 
symptoms, metacognition, and coping behaviour coincided with each other. However, due to 472 
the design of the study, the results provide no clarity with respect to causal relationships. In 473 
sum, large effect sizes and high recovery rates indicate that g-MCT is an effective treatment 474 
for GAD.  475 
 476 
With respect to treatment feasibility, 23 patients received treatment, while 22 patients were 477 
excluded. GAD not being the primary diagnosis (n = 9) was the most common reason for 478 
exclusion. Six patients (19 %) declined g-MCT in favour of individual MCT, and three 479 
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patients (9%) were unable to attend due to scheduling conflicts. Thus, 28% of participants 480 
who were offered treatment chose not to participate. This rate is slightly higher compared to a 481 
previous RCT study (19.8% [20 of 101 eligible patients]) offering individual treatment 482 
(Nordahl et al., 2018). Group treatment could also be less flexible than individual treatment 483 
which could exclude patients with set or busy schedules. On the other hand, a positive aspect 484 
is that none of the included patients dropped out during treatment, suggesting that g-MCT was 485 
accepted by the participants. Furthermore, the average number of therapist hours per patient 486 
in this study was 6.5 hours, which accounts for fewer hours per patient compared to studies 487 
using individual therapy (typically 10-12 sessions). Thus, g-MCT appear to be a cost-488 
effective treatment method. 489 
 490 
According to benchmarking analyses, patients in the current study had quite high scores on 491 
PSWQ at pre-treatment, while post-treatment and follow-up scores were comparable to 492 
previous investigations of individual MCT for GAD (Wells et al., 2010; Nordahl et al., 2018; 493 
van der Heiden et al., 2012). The recovery rate (PSWQ) at post-treatment in this study was 494 
65.3%, which is somewhat lower than Wells et al. (2010). This might be explained by the 495 
high pre-treatment scores in the current study. However, the recovery rate increased to 78.3% 496 
at 3-month follow-up, which is in line with results from individual MCT. The group study of 497 
van der Heiden et al. (2013) showed somewhat lower recovery rates than the current study. It 498 
could be speculated that this is related to differences in group size (4-6 patients vs. 10-14 499 
patients per group), but it could also be related to therapist factors, as two of their four 500 
therapists had not received MCT training. When comparing uncontrolled within effect sizes 501 
for studies on MCT for GAD, the current study showed promising results. However, the 502 
effect size estimation could be inflated and influenced by the relatively small sample size. The 503 
results are also encouraging when compared to recovery rates in CBT. As previously 504 
mentioned 50-60% are recovered following CBT for GAD (Fisher & Durham, 1999), and 505 
only 38% were recovered in a recent study (Nordahl et al., 2018).  506 
 507 
Group-MCT was associated with significant reductions in positive and negative 508 
metacognitions. The reduction was greater for the negative metacognitive beliefs than for 509 
positive beliefs. A possible explanation could be that patients reported fewer positive than 510 
negative metacognitive beliefs at the start of treatment. 511 
 512 
Treatment was also associated with reduction in symptoms of depression and comorbidity did 513 
not affect treatment outcome. This is an appealing aspect of treatment given the high rate of 514 
comorbidity (and overlap in symptoms) between GAD and depression. This finding is also 515 
consistent with studies showing that MCT has an effect on comorbid disorders (e.g. 516 
Capobianco et al., 2018; Johnson et al., 2017; Papageorgiou et al., 2018). The fact that 517 
treatment reduced comorbid symptoms of depression is also consistent with a metacognitive 518 
understanding of common underlying psychological processes in emotional disorders, and 519 
therefore supports a transdiagnostic utility of MCT. 520 
 521 
The study is not without limitations. The most obvious is the open trial design lacking a 522 
control group. Therefore, the study is unable to control for random fluctuations, spontaneous 523 
recovery, or effect of external variables. Evaluation of treatment effectiveness was also based 524 
on self-reported symptoms, which poses certain limitations such as social desirability. 525 
However, this effect could also be present for interview based ratings. Diagnostic re-526 
assessment at long term follow-up is ongoing. Another issue is that it was a predominantly a 527 
female sample, as well as a probable overrepresentation of patients with comorbid OCD. A 528 
strength of the study is however that treatment outcomes were comparable for patients with 529 
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and without comorbid disorders. Furthermore, there was no official measure of adherence. 530 
However, video supervision was conducted with an international expert in MCT and several 531 
groups had been conducted for training purposes before the open trial was initiated. Another 532 
issue is that diagnostic interviews were not videotaped and there is no measure of inter-rater 533 
agreement. Sample size is also an issue for the comorbidity analyses and comparing results 534 
across treatment studies is not always straightforward as samples and conditions may vary. 535 
 536 
In conclusion, the results of this study show that g-MCT was a suitable and effective 537 
treatment for patients with GAD. Treatment was associated with significant reductions in 538 
worry, anxiety, dysfunctional metacognitions, and coping strategies. It was also associated 539 
with significant improvement in symptoms of depression, which supports the transdiagnostic 540 
effects of MCT. Effect sizes were high and recovery rates were comparable to previous 541 
studies. The study supports further evaluation of group-MCT for patients with GAD using 542 
larger sample sizes and controlled designs. 543 
  544 
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Tables 677 
 678 
Table 1. Demographic and Diagnostic Characteristics of the Sample (N = 23) 679 
             680 
       n   % 681 
             682 
 Female     22   95.7 683 
 Single        7   30.4  684 
 Married/cohabitant    16   69.6 685 
Full time employed    11   47.8 686 
 Student       8   34.8 687 
 Welfare benefits      4   17.4 688 
 Current use of antidepressants     4   17.4 689 
 Previous psychiatric outpatient treatment 22   95.7 690 
  691 
Comorbidity 692 
    Obsessive-compulsive disorder   6   26.1 693 
    Depression      4   17.4 694 
    Panic disorder     4   17.4 695 
    Social anxiety disorder    2     8.7 696 
    Specific phobia     1     4.3 697 
    Health anxiety     1     4.3 698 
    ADHD      2     8.7 699 
Note. Patients diagnosed with ADHD were already diagnosed with ADHD as described in 700 
their referral. 701 
 702 
 703 
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Table 2. Repeated Measures ANOVA Testing Change in Symptoms and Metacognitions. 705 
 Pre Post F-U F Part. 
Eta sq. 
d  
 
d  
 M(SD)   Post Follow-up 
PSWQ 71.52 
(5.97) 
38.35 
(14.02) 
35.04 
(13.71) 
  78.38*** .88  2.42 2.95 
GAD-7 14.17 
(3.97) 
  3.83 
(3.38) 
  3.70 
(2.77) 
  78.39*** .88 2.30 2.34 
PHQ-9 13.87 
(5.55) 
  4.70 
(4.03) 
  4.91 
(5.11) 
  32.15*** .75 1.76 1.38 
GADS-R        
   Negative 67.17 
(21.70) 
  4.71 
(12.62) 
  4.78 
(12.50) 
136.62*** .86 2.55 2.56 
   Positive 29.78 
(25.87) 
  2.97 
(6.19) 
  1.88 
(4.06) 
  23.51*** .52 1.11 1.34 
   Coping   4.35 
(1.21) 
  0.76 
(0.90) 
  0.79 
(0.84) 
  91.04*** .90 2.54 2.82 
   Avoidance   2.96 
(1.31) 
  0.38 
(0.67) 
  0.44 
(0.68) 
  45.37*** .81 2.00 2.13 
Note. Greenhouse-Geisser correction used for PHQ-9, and negative- and positive beliefs.  706 
Effect sizes (Cohen’s d, 1992) were calculated using Morris & Deshon’s equation nr. 8 707 
controlling for correlation between pre- and post-treatment value for the variable in question. 708 
PSWQ = Penn State Worry Questionnaire, GAD-7 = Generalized Anxiety Disorder-7, PHQ-9 709 
= Patient Health Questionnaire-9, GADS-R = Generalized Anxiety Disorder Scale-Revised. 710 
  711 
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Table 3. Recovery rates (percentages) at post-treatment and follow-up 712 
 Deterioration No change Improved Recovered 
PSWQ     
   Post-treatment 0.0   4.3 30.4 65.3 
   Follow-up 0.0   4.3 17.4 78.3 
GAD-7     
   Post-treatment 0.0   4.3   8.7 87.0 
   Follow-up 0.0   0.0 21.7 78.3 
PHQ-9     
   Post-treatment 0.0   8.7 39.1 52.2 
   Follow-up 0.0 13.0 21.7 65.3 
Note. PSWQ = Penn State Worry Questionnaire, GAD-7 = Generalized Anxiety Disorder-7, 713 
PHQ-9 = Patient Health Questionnaire-9. Cut-off values for GAD-7 and PHQ-9 was set at > 714 
10. Improved = at least 7-points improvement on PSWQ or below cut-off. Recovered = 715 
criterion for improved and scoring 47 or less on PSWQ. 91.3% of participants scored above 716 
cut-off on GAD-7 at pre-treatment, and 73.9% scored above cut-off on PHQ-9. The two 717 
patients that scored below cut-off on GAD-7 at pre-treatment were not classified as recovered 718 
(probably due to low pre-treatment values).  719 
  720 
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Table 4. Changes on GADS-R from session to session 721 
 Symptoms Worry Negative 
beliefs 
Positive 
beliefs 
Coping 
strategies 
Avoidance 
 M SD M SD M SD M SD M SD M SD 
Pre 5.3 1.1 5.5 1.3 5.4 1.7 2.4 2.1 4.3 1.2 3.0 1.3 
1 5.4 1.1 5.2 0.9 5.3 1.2 3.0 2.3 4.4 1.0 2.6 1.0 
2 4.9 1.3 5.0 1.4 4.4 1.7 2.0 1.7 3.6 1.2 2.0 1.2 
3 4.3 1.4 4.2 1.7 3.5 1.6 1.4 1.3 3.2 1.3 1.7 1.1 
4 4.1 1.6 3.9 2.0 3.2 1.9 1.2 1.2 2.6 1.6 1.4 1.1 
5 3.8 1.8 3.4 1.8 2.1 1.8 0.9 0.9 2.0 1.3 1.1 1.1 
6 3.4 1.6 2.5 1.7 1.8 1.8 0.5 0.8 1.6 1.2 0.7 0.6 
7 2.4 1.3 1.8 1.2 0.8 1.1 0.5 0.9 1.1 1.0 0.6 0.7 
8 2.3 1.8 1.8 1.4 0.6 1.1 0.4 0.7 1.1 1.2 0.6 0.8 
9 2.3 2.0 1.8 1.7 0.5 0.8 0.2 0.6 0.8 0.7 0.4 0.5 
Post 2.0 1.4 1.3 1.3 0.2 0.3 0.2 0.5 0.7 0.9 0.3 0.6 
F-U 1.4 1.2 1.0 1.0 0.1 0.2 0.1 0.1 0.5 0.6 0.2 0.6 
Note. Changes from session to session (pre-treatment to 3-month follow-up) in GAD 722 
symptoms, worry, negative- and positive metacognitions, maladaptive coping strategies, and 723 
avoidance. All scores are transformed to a 0-8 scale.  724 
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Figures 725 
 726 
 727 
Figure 1. Flow chart 728 
 729 
 730 
Figure 2. Comparison of uncontrolled effect sizes in GAD trials using MCT. 731 
 732 
Note. All data are based on intention-to-treat and effect sizes are calculated using pooled 733 
standard deviations. All outcomes are assessed using the PSWQ.  734 
 735 
 736 
 737 
 738 
 739 
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